Neuro-oncology and supportive care: the role of the neurologist
- PMID: 34988720
- DOI: 10.1007/s10072-021-05862-3
Neuro-oncology and supportive care: the role of the neurologist
Abstract
The diagnosis of a brain tumor is a life-changing event for patients and their families. Despite numerous treatment advances, malignant brain tumors are universally incurable and long-term survival is limited. Treatment response, prognosis, and survival depend on underlying histopathology and recently defined molecular features. Patients suffer from a disproportionately high symptom burden throughout the disease trajectory and at the end of life. Pronounced neurologic decline and psychological distress significantly impair quality of life (QoL) and impose high supportive care needs relative to other systemic cancers. Palliative interventions addressing brain tumor-specific symptoms, such as seizures, cognitive dysfunction, and headaches, are paramount to maintaining QoL. In the terminal phase of illness, most brain tumor patients lose the ability to communicate and participate in end-of-life decision-making. The benefits of advance care planning and early integration of specialized palliative care are well-established in other systemic cancers and have received wider recognition in neuro-oncology. We review how to approach neurological symptoms in brain tumor patients, as well as address prognosis and advance care planning with the goal of improving QoL for patients and caregivers.
Keywords: Brain tumor; End of life; Glioblastoma; Palliative care; Quality of life; Supportive care.
© 2022. Fondazione Società Italiana di Neurologia.
References
-
- Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C (2017) Barnholtz-Sloan JS (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol 22:iv1–iv96. https://doi.org/10.1093/neuonc/noaa200 - DOI
-
- Poon MTC, Sudlow CLM, Figueroa JD, Brennan PM (2020) Longer-term (>/= 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci Rep 10:11622. https://doi.org/10.1038/s41598-020-68011-4 - DOI - PubMed - PMC
-
- Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106 - DOI - PubMed
-
- Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316. https://doi.org/10.1001/jama.2017.18718 - DOI - PubMed - PMC
-
- Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review. J Neurooncol 117:217–224. https://doi.org/10.1007/s11060-014-1393-6 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
